Lifevantage (LFVN) vs NeOnc Technologies (NTHI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lifevantage (LFVN) has outperformed NeOnc Technologies (NTHI) over the past year, losing 34.9% versus a loss of 79.1%. Lifevantage is the larger company by market cap ($75.4 million vs $72.9 million), about 1.0 times the size. Lifevantage pays a dividend yielding 3.09%, while NeOnc Technologies does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LFVN | NTHI |
|---|---|---|
| Share price | $5.99 | $2.53 |
| Market cap | $75.41M | $72.88M |
| 1-day change | -0.17% | -6.64% |
| YTD return | -2.76% | -69.41% |
| 1-year return | -34.89% | -79.07% |
| 5-year return | -12.17% | — |
| P/E ratio (TTM) | 14.97 | — |
| Forward P/E | 15.49 | — |
| EPS (TTM) | $0.40 | $-2.13 |
| Dividend yield | 3.09% | 0.00% |
| Annual dividend | $0.185 | $0.00 |
| 52-week high | $11.71 | $12.09 |
| 52-week low | $3.90 | $2.52 |
| Distance from 52-week high | -48.85% | -79.07% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +25.21% | +571.94% |
| Average volume | 59.73K | 195.17K |
| Shares outstanding | 12.59M | 28.81M |
| Employees | 209 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LFVN has outperformed NTHI by 44.2 percentage points over the past year.
- Lifevantage offers a meaningfully higher dividend yield (3.09% vs 0.00%).
About Lifevantage
LFVN stock →LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, gut health, and skin and hair care products in the United States and internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; LifeVantage Daily Wellness, a dietary supplement to strengthen immune health; LifeVantage Rise AM and Reset PM System that provides the body with the right nutrients; LifeVantage D3+, a dietary supplement that provides vitamin D3 and K2, magnesium, calcium, and other trace minerals to support a balanced immune system, strong bones, and cardiovascular health; P84 System, a product activator consisting of PhytoPower 1 and PhytoPower 2 that contains probiotics, prebiotics, postbiotics, digestive enzymes, and superfood blends designed to support gut health; MindBody GLP-1 System, a dietary supplement that combines two products, MB Core and MB Enhance, which are designed to support weight management and wellness by activating GLP-1 naturally and balancing signals along the gut-brain axis; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.
Health Care · Biotechnology: Pharmaceutical Preparations · 209 employees
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
LFVN vs NTHI FAQ
Which is bigger, Lifevantage or NeOnc Technologies?
Lifevantage (LFVN) is larger, with a market capitalization of $75.41M compared with $72.88M for NeOnc Technologies (NTHI).
Which stock has performed better over the past year, LFVN or NTHI?
LFVN returned -34.89% over the past 12 months, compared with -79.07% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Lifevantage or NeOnc Technologies?
Lifevantage pays a dividend yielding 3.09%, while NeOnc Technologies does not currently pay a regular dividend.
Are Lifevantage and NeOnc Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.